Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Galeotti, Caroline ^a,b,c,d   Hegde, Pushpa ^a,c   Das, Mrinmoy ^a,b,c   Stephen Victor, Emmanuel ^a,b,c   Canale, Fernando ^a,c   Muñoz, Marcos ^a,c   Sharma, Varun K ^a,c   Dimitrov, Jordan D ^a,b,c,e   Kaveri, Srini V ^a,b,c,e,f   Bayry, Jagadeesh ^a,b,c,e,f  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f NATIONAL INSTITUTE OF IMMUNOHAEMATOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; HEME OXYGENASE 1; IMMUNOGLOBULIN; PROTECTIVE AGENT;

ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL PROTECTION; DENDRITIC CELL; DRUG EFFECTS; ENZYME INDUCTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; MACROPHAGE; METABOLISM; MONOCYTE; MOUSE; RAW 264.7 CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CYTOPROTECTION; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INDUCTION; HEME OXYGENASE-1; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES; PROTECTIVE AGENTS; RAW 264.7 CELLS;

EID: 84955515806     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19592     Document Type: Article

References (60)

1. Arnson, Y., Shoenfeld, Y. & Amital, H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity 42, 553-560 (2009).
2. Bayry, J., Negi, V. S. & Kaveri, S. V. Intravenous immunoglobulin therapy in rheumatic diseases. Nat. Rev. Rheumatol. 7, 349-359 (2011).
3. Lunemann, J. D., Nimmerjahn, F. & Dalakas, M. C. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat. Rev. Neurol. 11, 80-89 (2015).
4. Greco, A. et al. Kawasaki disease: an evolving paradigm. Autoimmun. Rev. 14, 703-709 (2015).
5. Buttmann, M., Kaveri, S. & Hartung, H. P. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. Trends Pharmacol. Sci. 34, 445-457 (2013).
6. Ballow, M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315-323(2011).
7. Seite, J. F., Shoenfeld, Y., Youinou, P. & Hillion, S. What is the contents of the magic draft IVIg? Autoimmun. Rev. 7, 435-439 (2008).
8. Tha-In, T., Bayry, J., Metselaar, H. J., Kaveri, S. V. & Kwekkeboom, J. Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immmunol. 29, 608-615 (2008).
9. Gelfand, E. W. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367, 2015-25 (2012).
10. Danieli, M. G. et al. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun. Rev. 13, 1182-1188 (2014).
11. Anthony, R. M., Wermeling, F., Karlsson, M. C. & Ravetch, J. V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. USA 105, 19571-19578 (2008).
12. Crow, A. R., Song, S., Semple, J. W., Freedman, J. & Lazarus, A. H. A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 109, 155-158 (2007).
13. Seite, J. F., Goutsmedt, C., Youinou, P., Pers, J. O. & Hillion, S. Intravenous immunoglobulin induces a functional silencing program similar to anergy in human B cells. J. Allergy Clin. Immunol. 133, 181-188 (2014).
14. Jordan, S. C., Toyoda, M. & Vo, A. A. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88, 1-6 (2009).
15. Schwab, I. & Nimmerjahn, F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13, 176-189 (2013).
16. Sharma, M. et al. Intravenous immunoglobulin-induced IL-33 is insufficient to mediate basophil expansion in autoimmune patients. Sci. Rep. 4, 5672, doi: 10.1038/srep05672 (2014).
17. Campbell, I. K. et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J. Immunol. 192, 5031-5038 (2014).
18. Maddur, M. S. et al. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. J. Clin. Immunol. 30 (Suppl 1), S4-S8 (2010).
19. Cousens, L. P. et al. Tregitope update: mechanism of action parallels IVIg. Autoimmun. Rev. 12, 436-443 (2013).
20. Nagelkerke, S. Q. et al. Inhibition of FcgammaR-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and FcgammaRIIb in human macrophages. Blood 124, 3709-3718 (2014).
21. Galeotti, C., Kaveri, S. V. & Bayry, J. Molecular and immunological biomarkers to predict IVIg response. Trends Mol. Med. 21, 145-147 (2015).
22. Abraham, N. G. & Kappas, A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev. 60, 79-127 (2008).
23. Chora, A. A. et al. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. J. Clin. Invest. 117, 438-447(2007).
24. Chung, S. W., Liu, X., Macias, A. A., Baron, R. M. & Perrella, M. A. Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J. Clin. Invest. 118, 239-247 (2008).
25. Hu, C. M., Lin, H. H., Chiang, M. T., Chang, P. F. & Chau, L. Y. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 56, 1240-1247 (2007).
26. Willis, D., Moore, A. R., Frederick, R. & Willoughby, D. A. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nat. Med. 2, 87-90 (1996).
27. Shiloh, M. U., Manzanillo, P. & Cox, J. S. Mycobacterium tuberculosis senses host-derived carbon monoxide during macrophage infection. Cell Host Microbe 3, 323-330 (2008).
28. Pae, H. O. et al. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J. Immunol. 172, 4744-4751 (2004).
29. Yachie, A. et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J. Clin. Invest. 103, 129-135 (1999).
30. Xia, Z. W. et al. Heme oxygenase-1 attenuates ovalbumin-induced airway inflammation by up-regulation of foxp3 T-regulatory cells, interleukin-10, and membrane-bound transforming growth factor- 1. Am. J. Pathol. 171, 1904-1914 (2007).
31. Zelenay, S., Chora, A., Soares, M. P. & Demengeot, J. Heme oxygenase-1 is not required for mouse regulatory T cell development and function. Int. Immunol. 19, 11-18 (2007).
32. Otterbein, L. E., Soares, M. P., Yamashita, K. & Bach, F. H. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24, 449-455 (2003).
33. Otterbein, L. E. et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6, 422-428 (2000).
34. Rushworth, S. A., MacEwan, D. J. & O'Connell, M. A. Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes. J. Immunol. 181, 6730-6737 (2008).
35. Chauveau, C. et al. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 106, 1694-1702 (2005).
36. Remy, S. et al. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. J. Immunol. 182, 1877-1884 (2009).
37. Bayry, J. et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101, 758-765 (2003).
38. Tjon, A. S. et al. Intravenous immunoglobulin treatment in humans suppresses dendritic cell function via stimulation of IL-4 and IL-13 production. J. Immunol. 192, 5625-5634 (2014).
39. Padet, L., Loubaki, L. & Bazin, R. Induction of PD-L1 on monocytes: a new mechanism by which IVIg inhibits mixed lymphocyte reactions. Immunobiology 219, 687-694 (2014).
40. Trinath, J. et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood 122, 1419-1427 (2013).
41. Othy, S. et al. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J. Immunol. 190, 4535-4541 (2013).
42. Fiebiger, B. M., Maamary, J., Pincetic, A. & Ravetch, J. V. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. USA 112, E2385-E2394 (2015).
43. Maddur, M. S. et al. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J. Allergy Clin. Immunol. 127, 823-830 (2011).
44. Maddur, M. S. et al. Inhibitory effect of IVIG on IL-17 production by Th17 cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. J. Clin. Immunol. 33, S62-S66 (2013).
45. Maddur, M. S. et al. Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation. Cell. Mol. Immunol. 12, 650-652 (2015).
46. Kessel, A. et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J. Immunol. 179, 5571-5575(2007).
47. Bayry, J., Mouthon, L. & Kaveri S. V. Intravenous immunoglobulin expands regulatory T cells in autoimmune rheumatic disease. J. Rheumatol. 39, 450-451 (2012).
48. Massoud, A. H. et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J. Allergy Clin. Immunol. 133, 853-863 (2014).
49. Visner, G. A. et al. Rapamycin induces heme oxygenase-1 in human pulmonary vascular cells: implications in the antiproliferative response to rapamycin. Circulation 107, 911-916 (2003).
50. Nakahira, K. et al. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J. Exp. Med. 203, 2377-2389 (2006).
51. Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
52. Choi, B. M., Pae, H. O., Jeong, Y. R., Kim, Y. M. & Chung, H. T. Critical role of heme oxygenase-1 in Foxp3-mediated immune suppression. Biochem. Biophys. Res. Commun. 327, 1066-1071 (2005).
53. Biburger, M., Theiner, G., Schadle, M., Schuler, G. & Tiegs, G. Pivotal Advance: Heme oxygenase 1 expression by human CD4+ T cells is not sufficient for their development of immunoregulatory capacity. J. Leukoc. Biol. 87, 193-202 (2010).
54. George, J. F. et al. Suppression by CD4+ CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigenpresenting cells. Am. J. Pathol. 173, 154-160 (2008).
55. Zhang, Y., Zhang, L., Wu, J., Di, C. & Xia, Z. Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting Th17 cell-mediated immune response. J. Biol. Chem. 288, 34612-34626 (2013).
56. Farooq, S. M. & Ashour, H. M. Eye-mediated induction of specific immune tolerance to encephalitogenic antigens. CNS Neurosci. Ther. 19, 503-510 (2013).
57. Robinson, A. P., Harp, C. T., Noronha, A. & Miller, S. D. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 122, 173-189 (2014).
58. Bayry, J., Hartung, H. P. & Kaveri, S. V. IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties. Trends Pharmacol. Sci. 36, 419-421 (2015).
59. Maddur, M. S., Kaveri, S. V. & Bayry, J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun. Rev. 10, 809-810 (2011).
60. Maddur, M. S. et al. Human B cells induce dendritic cell maturation and favour Th2 polarization by inducing OX-40 ligand. Nat. Commun. 5, 4092, doi: 10.1038/ncomms5092 (2014).